Last Updated: September 25, 2026

Details for Patent: 11,338,007

Name: Drug Patent Intelligence for US Patent 11338007
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,338,007 protect, and when does it expire?

Patent 11,338,007 protects VOSEVI and is included in one NDA.

Protection for VOSEVI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventeen patent family members in seventeen countries.

Summary for Patent: 11,338,007

Title:	Combination formulation of three antiviral compounds
Abstract:	Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
Inventor(s):	Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
Assignee:	Gilead Sciences Inc
Application Number:	US16/306,424
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,338,007
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 11,338,007

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	VOSEVI	sofosbuvir; velpatasvir; voxilaprevir	TABLET;ORAL	209195-001	Jul 18, 2017		RX	Yes	Yes	11,338,007*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,338,007

PCT Information
PCT Filed	June 01, 2017	PCT Application Number:	PCT/US2017/035539
PCT Publication Date:	December 07, 2017	PCT Publication Number:	WO2017/210483

International Family Members for US Patent 11,338,007

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	108616	⤷ Start Trial
Australia	2017273851	⤷ Start Trial
Brazil	102017011025	⤷ Start Trial
Canada	3025380	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.